In This Article:
InMed Pharmaceuticals (NASDAQ:INM) Second Quarter 2025 Results
Key Financial Results
-
Revenue: US$1.11m (down 10% from 2Q 2024).
-
Net loss: US$2.58m (loss widened by 74% from 2Q 2024).
-
US$3.65 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
InMed Pharmaceuticals' share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for InMed Pharmaceuticals (3 are concerning!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.